522 related articles for article (PubMed ID: 32027523)
21. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P; Sandborn WJ
Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
[TBL] [Abstract][Full Text] [Related]
22. Targeting IL-23 in Crohn's disease.
Sedda S; Bevivino G; Monteleone G
Expert Rev Clin Immunol; 2018 Nov; 14(11):907-913. PubMed ID: 30223688
[TBL] [Abstract][Full Text] [Related]
23. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
24. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
25. Update on ustekinumab for the treatment of Crohn's disease.
Leung Y; Panaccione R
Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
[TBL] [Abstract][Full Text] [Related]
26. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease.
Aggeletopoulou I; Assimakopoulos SF; Konstantakis C; Triantos C
World J Gastroenterol; 2018 Sep; 24(36):4093-4103. PubMed ID: 30271076
[TBL] [Abstract][Full Text] [Related]
27. [Emerging Therapies: What Are Promising in the Near Future?].
Seo GS; Lee SH
Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
[TBL] [Abstract][Full Text] [Related]
28. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
29. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
Macaluso FS; Orlando A; Cottone M
Expert Opin Biol Ther; 2019 Feb; 19(2):89-98. PubMed ID: 30571147
[TBL] [Abstract][Full Text] [Related]
30. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
31. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.
Benson JM; Peritt D; Scallon BJ; Heavner GA; Shealy DJ; Giles-Komar JM; Mascelli MA
MAbs; 2011; 3(6):535-45. PubMed ID: 22123062
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.
Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S
Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049
[TBL] [Abstract][Full Text] [Related]
33. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
34. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
Verstockt B; Salas A; Sands BE; Abraham C; Leibovitzh H; Neurath MF; Vande Casteele N;
Nat Rev Gastroenterol Hepatol; 2023 Jul; 20(7):433-446. PubMed ID: 37069321
[TBL] [Abstract][Full Text] [Related]
35. Reduced CD27
Pararasa C; Zhang N; Tull TJ; Chong MHA; Siu JHY; Guesdon W; Chavele KM; Sanderson JD; Langmead L; Kok K; Spencer J; Vossenkamper A
Front Immunol; 2019; 10():361. PubMed ID: 30891036
[TBL] [Abstract][Full Text] [Related]
36. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
Sandborn WJ; Feagan BG; Fedorak RN; Scherl E; Fleisher MR; Katz S; Johanns J; Blank M; Rutgeerts P;
Gastroenterology; 2008 Oct; 135(4):1130-41. PubMed ID: 18706417
[TBL] [Abstract][Full Text] [Related]
38. Ustekinumab: moving the target from psoriasis to Crohn's disease.
Settesoldi A; Coppola M; Rogai F; Annese V
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):5-13. PubMed ID: 24410468
[TBL] [Abstract][Full Text] [Related]
39. Ustekinumab: The "New Kid on the Block" in the Treatment of Psoriatic Arthritis.
Torres T; Faria R
Drug Dev Res; 2015 Dec; 76(8):428-31. PubMed ID: 26372543
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
